Remove topics oral-argument
article thumbnail

See you Soon: Three Upcoming Events

Patently-O

GM, with oral arguments scheduled for February 5, 2024. Oral arguments will include the 11 Federal Circuit judges (absent Judge Newman) along with Mark Lemley (for the accused infringer); Joe Herriges (for the patentee GM); and USPTO Acting Solicitor Farheena Rasheed (for amicus USPTO).

article thumbnail

Bottles Up

LexBlog IP

As a firm of trademark and alcohol attorneys, it’s always a thrill when those two topics collide, especially on a major stage. Oral arguments were heard last week. We had one of those great moments of serendipity last week. In 2017, Diageo sued W.J. But wait, what about Bulleit and last week?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The appeal of rulings

Olartemoure Blog

This led to the emergence of contradictory points of view within the courts: the first consisted on declaring the deserted, not supported, appeal; and, the second, aimed to resolve it based on the arguments that were presented before the judge of first instance.

article thumbnail

Got Milk? Forget about Patent Eligibility

Patently-O

The Federal Circuit weighed in on the amorphous topic of subject matter eligibility in the recent opinion ChromaDex, Inc., Although the claims require isolated NR, they do not require a specific high-concentration, only enough to “increase[] NAD+ biosynthesis upon oral administration.” Elysium Health, Inc. , — F.4th

Patent 55
article thumbnail

Patents & the Magical World of Psychedelics

IPilogue

Although the Canadian legalization of psilocybin, similar to cannabis, is an interesting and contentious topic, this article intends to highlight the potential patentability of psilocybin and its derivatives, as well as the current trends in the field. In 2020, the sales of cannabis products hit $2.6 Current Trends in Psychedelic Patenting.

Patent 59
article thumbnail

Seeing Clearly: Article III Standing of IPR Judicial Review

Patently-O

Article III standing remains a hot topic at all levels of federal litigation and across many different areas of law. With surgery as the only viable course of treatment, Cloudbreak Therapeutics created a topical application of multikinase inhibitors to provide a non-surgical treatment to prevent recurring tumors, which is recognized in U.S.

Art 49
article thumbnail

Jury Instructions and Objective Indicia of Nonobviousness: Federal Circuit Grants New Trial in Inline Plastics v. Lacerta

Patently-O

At the close of trial, jury instructions are typically given orally by the judge and can also be provided to the jury in writing for reference during deliberations. However, the Federal Circuit rejected this argument.